Success Story: Advancing Nanoparticle Drug Delivery for Metastatic Breast Cancer: NIW Approval Secured for a Pharmaceutical Science Researcher from Nepal
Client’s Testimonial:
"I would like to express my sincere gratitude to Chen Immigration for their exceptional support throughout the process. From the initial evaluation to the final submission, the Chen Immigration team demonstrated outstanding professionalism, expertise, and attention to detail. They provided clear guidance at every stage, responded promptly to my questions, and helped me present my qualifications and achievements in the strongest possible manner.
What impressed me most was their deep understanding of the EB2-NIW process and their meticulous approach to preparing the petition package. Their experience and strategic advice gave me confidence throughout the journey and significantly reduced the stress associated with the application process. I highly recommend Chen Immigration to anyone pursuing an EB2-NIW petition. Their dedication, responsiveness, and professionalism played an important role in the successful approval of my I-140 petition.
Thank you again to the entire Chen Immigration team for your outstanding work and support.”
On June 16th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Research Assistant in the field of Pharmaceutical Science (Approval Notice).
General Field: Pharmaceutical Science
Position at the Time of Case Filing: Graduate Research Assistant
Country of Origin: Nepal
State of Residence at the Time of Filing: Texas
Approval Notice Date: June 16th, 2026
Processing Time: 1 month, 24 days (Premium Processing Requested)
Case Summary:
The client’s work focuses on a critical challenge in cancer treatment, namely, how to improve drug delivery and immune response in metastatic breast cancer therapy. Her proposed endeavor centered on engineering and validating immune-modulating nanoparticle delivery platforms using metal-phenolic frameworks and messenger ribonucleic acid (mRNA) lipid nanoparticles (LNPs). At the time of filing, she was conducting pharmaceutical science research at a U.S. university, where her work involved nano-drug delivery systems, immune-modulating platforms, mRNA-LNP delivery, and targeted therapeutic approaches for metastatic breast cancer.
Research with National Importance
Her research addresses a critical need in oncology, the development of more effective and targeted treatment strategies for metastatic cancers that remain difficult to treat with conventional approaches. By working on engineered delivery platforms and responsive therapeutic systems, her research contributes to improving how drugs interact with biological systems and how treatment responses can be enhanced at the cellular level. Her work supports broader efforts in precision medicine and cancer immunotherapy by advancing approaches that improve targeted delivery, therapeutic efficiency, and treatment safety.
Academic Contributions and Recognition
At the time of filing, the client’s record included 6 peer-reviewed journal articles, 1 first-authored conference abstract, and 72 citations, with several papers cited at notable rates in Pharmacology and Toxicology, including 1 paper ranked within the top 1% and 2 papers ranked within the top 10% for their publication years. We demonstrated her significance through her publication record, citation impact, highly ranked publication venues, expert recommendation letter, and documented reliance on her findings by independent researchers, including studies involving breast cancer nano-drug delivery, dual-action nanoplatforms, pH-responsive drug release, mRNA delivery stability, and next-generation RNA therapeutic delivery systems.
Expert Endorsements
The recommendation letter submitted with the petition emphasized the client’s expertise in pharmaceutical science, nano-drug delivery, mRNA-LNP systems, and immune-modulating nanoparticle platforms. The expert highlighted that her research addresses key limitations in metastatic breast cancer treatment, including drug resistance, systemic toxicity, and the need for more targeted therapeutic delivery. One expert stated:
“[Client]’s skillset is irreplaceable, given its immense benefits to metastatic breast cancer therapy. It is imperative that she be allowed to carry out her research uninterrupted so that the United States is able to benefit fully from its value.”
This endorsement helped show that the client’s work has practical significance beyond her individual publication record. Together with her citation impact, highly ranked publication venues, documented use by independent researchers, and continued research plans, the expert support strengthened the petition’s argument that her contributions are significant to pharmaceutical science, precision oncology, and cancer therapy research.
NIW Approval and Outlook
The I-140 NIW petition was filed on April 23rd, 2026, with Premium Processing Requested and approved on June 16th, 2026. The approval recognized the national importance of the client’s work in pharmaceutical science, particularly her research on immune-modulating nanoparticle delivery platforms, mRNA-LNP systems, targeted drug delivery, and metastatic breast cancer treatment.
This result supports the client’s continued work in developing nanoparticle-based therapeutic strategies that can improve cancer treatment and advance precision medicine. We congratulate her on this approval and wish her continued success in contributing to pharmaceutical science and cancer therapy research in the United States.